Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

EMST 150 Training in Mild-Moderate OSA

10 november 2026 uppdaterad av: Thomaz Fleury Curado, University Hospitals Cleveland Medical Center

Evaluating the Efficacy and Feasibility of Combined Expiratory Muscle Strength Training (EMST 150) and Oropharyngeal Myofunctional Therapy in Patients With Mild-to-Moderate Obstructive Sleep Apnea.

Obstructive Sleep Apnea is a condition in which the upper airway repeatedly becomes blocked during sleep, often due to weakness or collapse of the upper airway throat muscles. The purpose of this study is to evaluate whether combining a handheld breathing device (Expiratory Muscle Strength Training (EMST 150)) with structured, speech-language pathology-Guided mouth and throat exercises can help strengthen the muscles that keep the airway open, reduce snoring, and reduce sleep apnea severity while improving overall sleep quality. Participation in this study will last about 3 months. This includes a 5-week home breathing exercise program, two in-person clinic visits (at the beginning of the study and at Month 3), and two short phone check-ins.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

20

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • University Hospitals Cleveland Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Clinical diagnosis of Mild-to-Moderate OSA (5<AHI<30 events/hour)
  • Patient willingness and physical capability to perform threshold-based respiratory exercises and daily oral myofunctional exercises.
  • Documented failure, intolerance (defined as regular use < 4 hours/night), or patient refusal of standard therapies, including Continuous Positive Airway Pressure (CPAP) and surgical interventions.

Exclusion Criteria:

  • Severe OSA (AHI>30 events/hour)
  • Active asthma, severe or poorly controlled asthma with low symptom perception, or severe chronic obstructive pulmonary disease (COPD)
  • Uncontrolled hypertension, defined as resting systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening, or any change in antihypertensive medication within the past 30 days, or significant cardiovascular disease.
  • Recent esophageal surgery, recent abdominal surgery, or presence of an abdominal hernia.
  • History of spontaneous pneumothorax, or incomplete recovery/healing following traumatic pneumothorax or rib fracture.
  • History of lung transplantation or lung resection.
  • Current tracheostomy or unhealed tracheostomy stoma.
  • Presence of a cerebrospinal fluid (CSF) drain or active intracranial pressure monitoring.
  • Active epistaxis (frequent/severe nosebleeds) or active hemoptysis within the past 30 days.
  • Tympanic membrane perforation (ruptured eardrum) or active inner/middle ear pathology.
  • Unrelated or uncontrolled gastroesophageal reflux disease (GERD).
  • Known or suspected pregnancy.
  • Active use of CPAP, mandibular advancement device (MAD), or hypoglossal nerve stimulation (HGNS) during the study period.
  • Any acute medical condition or clinical situation where generating intrathoracic, intro-abdominal, or intracranial pressure (similar to Valsalva maneuver) is clinically contraindicated.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Participants with Obstructive Sleep Apnea (OSA)

Adult participants diagnosed with mild-to-moderate obstructive OSA.

Participants utilize the EMST 150 device to strengthen expiratory and upper airway musculature. During training, participants inhale deeply and exhale forcefully through the mouthpiece again calibrated resistance while maintaining an airtight lip seal to overcome the target threshold pressure.

Participants perform structured oral motor exercises :

  • Lingual maneuvers
  • Soft palate and velopharyngeal exercises
  • Facial and buccinator muscle conditioning to reinforce nasal breathing.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI)
Tidsram: Baseline, 3 months

The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that evaluates overall sleep quality and disturbances over a one-month time interval. With higher scores indicating poor sleep quality.

Baseline, 3 months
Change in Daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS)
Tidsram: Baseline, 3 months

The Epworth Sleepiness Scale (ESS) is a short, self-administered questionnaire used to measure a person's general level of daytime sleepiness and likelihood of dozing off in everyday situations. Scored on a scale from 0 would never doze, to 3 high chance of dozing.

Baseline, 3 months
Snore score as measured by smartphone application monitoring.
Tidsram: Up to 3 months

Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

Up to 3 months
Percentage of snoring sleep time as measured by smartphone application monitoring.
Tidsram: Up to 3 months

Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

Up to 3 months
Noise intensity in decibels as measured by smartphone application monitoring.
Tidsram: Up to 3 months

Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

Up to 3 months
Change in Isometric maximal tongue pressure (kPa) as measured by the Iowa Oral Performance Instrument (IOPI)
Tidsram: Baseline, 3 months

The Iowa Oral Performance Instrument (IOPI) is a portable, evidence-based medical device used to objectively measure, document, and train lip and tongue strength and endurance. The device digitally records maximum isometric pressure in kilopascals

Baseline, 3 months
Change in tongue muscle endurance as measured by time in seconds sustained at 50% maximal pressure.
Tidsram: Baseline, 3 months

Time in seconds sustained at 50% maximal pressure.

Baseline, 3 months
Change in Apnea-Hypopnea Index (AHI)
Tidsram: Baseline, 3 months

The apnea-hypopnea index (AHI) is the average number of breathing pauses (apneas) and shallow breathing events (hypopneas) that occur per hour of sleep, with higher scores indicating greater sleep apnea severity.

Baseline, 3 months
Change in Maximum Expiratory Pressure (MEP)
Tidsram: Baseline, 3 months

MEP is the highest positive pressure generated by a person during a forced exhalation against a blocked airway. It measures the strength of the expiratory muscles, including the abdominal and internal intercostal muscles, and helps evaluate cough efficiency and neuromuscular function. Lower scores indicate generalized respiratory muscle weakness, chronic obstructive pulmonary disease (COPD), or neuromuscular conditions like myasthenia gravis or Guillain-Barré syndrome.

Baseline, 3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Thomaz Fleury Curado, MD, University Hospitals Cleveland Medical Center

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 december 2026

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

17 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera